酮替芬联合舒利迭在哮喘合并变应性鼻炎治疗中的应用价值分析

摘要

Objective:To explore the application value of Ketotifen combined with Seretide in the treatment of asthma complicated with allergic rhinitis. Method:80 patients with bronchial asthma complicated with allergic rhinitis were selected in our hospital from May 2013 to February 2014,they were randomly divided into two groups,40 cases in each group.The treatment group was given Ketotifen for treatment,the control group was treated with Montelukast Sodium for treatment,during treatment two groups were also given Seretide,the treatment cycle for 3 months.The clinical efficacy and adverse reactions of two groups were compared. Result:After 3 months of treatment,the rhinitis symptoms of two groups were all improved,the rhinitis symptoms score and ACT score of treatment group were significantly better than the control group,the incidence of adverse reactions of treatment group was lower than that of the control group,PEF and FEV1 and other pulmonary function indexes of treatment group were significantly better than the control group,the differences were statistically significant(P<0.05).Conclusion:The curative effect of Ketotifen combined with Seretide in the treatment of asthma complicated with allergic rhinitis is distinct,it is better than Montelukast Sodium combined with Seretide,it has lower incidence of adverse reactions and higher security,it is worthy of promotion in clinical treatment.%目的：探究酮替芬联合舒利迭在哮喘合并变应性鼻炎治疗中的应用价值。方法：选取2013年5月-2014年2月期间本院门诊室的80例支气管哮喘合并变应性鼻炎患者，将其随机分为两组，每组各40例。其中治疗组给予酮替芬治疗，对照组给予孟鲁司特钠治疗，两组在治疗期间同时给予舒利迭治疗，治疗周期为3个月，比较两组的临床疗效及不良反应的发生情况。结果：经过3个月的治疗，两组治疗前后的鼻炎症状皆有所改善，治疗组的鼻炎症状评分、ACT评分显著优于对照组，不良反应发生率低于对照组，PEF和FEV1等肺功能指标结果均明显优于对照组，两组比较差异均有统计学意义（P<0.05）。结论：酮替芬联合舒利迭治疗哮喘合并变应性鼻炎的疗效显著，不亚于孟鲁司特钠联合舒利迭，且不良反应的发生率低，安全性较高，值得在临床治疗中推广。